Prelude Therapeutics Incorporated (PRLD)
- Previous Close
0.8216 - Open
0.8105 - Bid 0.7538 x 100
- Ask 0.8246 x 100
- Day's Range
0.7300 - 0.8547 - 52 Week Range
0.6100 - 6.8000 - Volume
108,154 - Avg. Volume
201,198 - Market Cap (intraday)
44.943M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6800 - Earnings Date May 6, 2025 - May 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.33
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
preludetx.comRecent News: PRLD
View More
Performance Overview: PRLD
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRLD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRLD
View MoreValuation Measures
Market Cap
46.39M
Enterprise Value
-69.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.90
Price/Book (mrq)
0.35
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.54%
Return on Equity (ttm)
-69.01%
Revenue (ttm)
7M
Net Income Avi to Common (ttm)
-127.17M
Diluted EPS (ttm)
-1.6800
Balance Sheet and Cash Flow
Total Cash (mrq)
133.61M
Total Debt/Equity (mrq)
13.71%
Levered Free Cash Flow (ttm)
-62M
Research Analysis: PRLD
View MoreResearch Reports: PRLD
View MoreDaily – Vickers Top Insider Picks for 05/06/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 05/05/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 05/02/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 05/01/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.